Business Context and Reporting Period
EUDA Health Holdings Limited filed a Form 8-K reporting the completion of its business combination with EUDA Health Limited on November 17, 2022. Formerly 8i Acquisition 2 Corp., the registrant acquired all outstanding shares of EUDA Health Limited, making it a wholly owned subsidiary, changed its name, and ceased to be a shell company. The report was signed and dated November 23, 2022.
Following closing, the ordinary shares and warrants began trading on Nasdaq under the symbols EUDA and EUDAW, respectively. The company also changed its fiscal year-end to December 31.
Financial Metrics and Liquidity
The filing does not provide a clear consolidated value for revenue, net income, operating cash flow, margins, debt, cash, or liquidity in the supplied text. It incorporates by reference EUDA Health Limited’s audited financial statements for 2020 and 2021, unaudited financial statements for the nine months ended September 30, 2022 and 2021, and unaudited pro forma combined financial information.
EUDA’s management’s discussion and analysis for the nine months ended September 30, 2022 is filed as Exhibit 99.2, but the underlying financial figures are not included in the supplied filing text. The report separately references 8i’s financial statements and quarterly report for the three months ended October 31, 2022.
Material Changes Versus the Prior Comparable Period
- Completed the acquisition of EUDA Health Limited and transitioned from a SPAC shell company to an operating healthcare company.
- Changed the legal name from 8i Acquisition 2 Corp. to EUDA Health Holdings Limited.
- Changed Nasdaq symbols from LAX, LAXXW and related pre-closing symbols to EUDA and EUDAW; the former units ceased trading after separation into their component securities.
- Adopted amended and restated memorandum and articles of association and a new Code of Business Conduct and Ethics.
- Changed the fiscal year-end to December 31.
- Replaced UHY LLP with Marcum Asia CPAs LLP as independent registered public accounting firm. Marcum previously audited EUDA Health Limited.
Guidance, Outlook, Risks, Contingencies and Unusual Items
No specific revenue, earnings, cash-flow, or operating guidance is provided in the supplied text. Management’s forward-looking statements are subject to risks involving market acceptance, profitability, funding needs, competition, cybersecurity, regulation, economic conditions, Nasdaq listing compliance, integration of the business combination, litigation, and the effects of COVID-19.
Seller and designated holders agreed to an 18-month lock-up, subject to specified exceptions and possible reduction by agreement. The company must file a resale registration statement covering registrable securities within 14 calendar days after closing; the registration rights agreement does not provide liquidated damages for delays.
The company entered into indemnification agreements with directors and executive officers and obtained directors’ and officers’ liability insurance. As of the report date, the company stated that it was not involved in litigation, investigations, or claims expected to have a material adverse effect.
UHY’s prior reports did not contain adverse opinions or disclaimers, but included substantial doubt regarding 8i’s ability to continue as a going concern. The filing states that there were no disagreements or reportable events leading to the auditor change.
Ownership and Capitalization Highlights
- Ordinary shares outstanding as of November 22, 2022: 22,370,650.
- Watermark Developments Limited beneficially owned 9,660,000 shares, or approximately 38.5%.
- Meng Dong (James) Tan beneficially owned 5,241,725 shares, or approximately 23.4%.
- Directors and executive officers as a group beneficially owned 1,079,075 shares, or approximately 5.3%.
Important Facts for Investors to Verify
- Review Exhibits 99.1 through 99.3 for EUDA’s historical financial results, liquidity, debt, cash flow, margins, and pro forma effects of the transaction.
- Confirm the final share count, earnout provisions, warrant terms, dilution potential, and ownership interests associated with Watermark and sponsor holdings.
- Review the registration rights and lock-up agreements for resale timing and potential increases in public-market share supply.
- Assess the going-concern history of the predecessor SPAC and EUDA’s post-closing funding requirements.
- Review the Proxy Statement risk factors and EUDA’s operating performance disclosures for regulatory, cybersecurity, competitive, integration, and profitability risks.
- Confirm the auditor transition from UHY to Marcum and monitor future audit opinions and internal-control disclosures.